Traws Pharma, Inc.
NASDAQ Global MarketTotal Valuation
Traws Pharma, Inc. carries a market capitalization of 13.25M, placing it among publicly traded companies globally.
| Market Cap | 13.25M |
| Enterprise Value | N/A |
Share Statistics
Traws Pharma, Inc. currently has 10.16M shares outstanding.
| Shares Outstanding | 10.16M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Traws Pharma, Inc. trades at a trailing price-to-earnings ratio of 0.49. The price-to-sales ratio is 5.64, and the price-to-book ratio stands at -0.02.
| PE Ratio | 0.49 |
| PS Ratio | 5.64 |
| PB Ratio | -0.02 |
| P/TBV Ratio | -1.98 |
| P/FCF Ratio | -1.01 |
| P/OCF Ratio | -1.01 |
Financial Position
Traws Pharma, Inc. maintains a current ratio of 0.43, meaning it holds 0.4x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 0.43 |
| Quick Ratio | 0.36 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -142.75 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Traws Pharma, Inc.'s stock has declined approximately -22.45989% over the past 52 weeks. The 50-day moving average sits at 1.58, while the 200-day moving average is 1.89.
| Beta (5Y) | N/A |
| 52-Week Price Change | -22.45989% |
| 50-Day Moving Average | 1.58 |
| 200-Day Moving Average | 1.89 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Traws Pharma, Inc. generated 2.73M in revenue and converted that into -19.43M in net income, yielding earnings per share of -2.31. EBITDA reached -19.51M, while operating income came in at -19.62M.
| Revenue | 2.73M |
| Gross Profit | N/A |
| Operating Income | -19.62M |
| Pretax Income | -19.43M |
| Net Income | -19.43M |
| EBITDA | -19.51M |
| EBIT | -19.62M |
| Earnings Per Share (EPS) | -2.31 |
Balance Sheet
Total book value stands at -646.99M, with working capital of -7.54M providing operational flexibility.
| Cash & Cash Equivalents | 3.13M |
| Total Debt | N/A |
| Net Debt | -3.13M |
| Equity (Book Value) | -646.99M |
| Book Value Per Share | -76.78 |
| Working Capital | -7.54M |
Cash Flow
Traws Pharma, Inc. produced -15.32M in operating cash flow over the past twelve months.
| Operating Cash Flow | -15.32M |
| Capital Expenditures | N/A |
| Free Cash Flow | -15.32M |
| FCF Per Share | -1.82 |
Margins
Traws Pharma, Inc. operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -717.82 and net profit margin of -710.83 provide insight into operational efficiency.
| Gross Margin | 100.00 |
| Operating Margin | -717.82 |
| Pretax Margin | -710.83 |
| Profit Margin | -710.83 |
| EBITDA Margin | -714.01 |
Dividends & Yields
The company's payout ratio of -20.18 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | -20.18 |
| Shareholder Yield | -32.99 |
| FCF Yield | -99.37 |
Stock Splits
Traws Pharma, Inc.'s most recent stock split took place on September 23, 2024 with a 25:1 split ratio.
| Last Split Date | 9/23/2024 |
| Split Ratio | 25:1 |
Scores
Traws Pharma, Inc. posts an Altman Z-Score of -171.56, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -171.56 |